Moving targets: COVID-19 vaccine efficacy against Omicron subvariants.
Moving targets: COVID-19 vaccine efficacy against Omicron subvariants.
复制标题
DOI：
10.1016/j.ymthe.2022.07.004
复制
发表时间：
2022-08-03
影响因子：
12.4
通讯作者：
Nobre Oliveira, Jonas Ivan
中科院分区：
文献类型：
--
作者：
da Silva, Maria Karolaynne;Fulco, Umberto Laino;da Silva Junior, Edilson Dantas;Nobre Oliveira, Jonas Ivan
最近，冠状病毒2型严重急性呼吸综合征（SARS-CoV-2）的欧米克隆变异在全球传播，对COVID-19疫苗和中和性治疗抗体的有效性构成了重大挑战。这是由于刺突蛋白(S)的多重突变，包括其受体结合结构域（RBD）和n端结构域。1-3年4月，BA。由广管局取代。2 subvariant。目前，BA。2.12. 1和BA。在美国和南非，4/5亚型的数量急剧增加并占主导地位。这些变异含有与BA相同的S蛋白RBD序列。2，但有额外的L452和F486突变，即L452Q （BA）。2.12. 1)、l452m (ba)；2.13), L452R， F486V和69-70缺失(BA。4/5)，且均表现出比BA更大的传播优势。2. 报道了BA穗残基F486V （L452）突变。4/5(两个BA。2.12. 1和BA。4/5)有助于逃避一些针对RBD的所谓1类和2类（2类和3类）的抗体，但会损害细胞受体血管紧张素转换酶2 （ACE2）的刺突亲和力。5然而，L452R和R493Q的逆转恢复了对hACE2的结合亲和力，从而恢复了BA的适应度。4/5。6尽管英航。2.12. 1和BA。4/5对BA具有相当的ACE2结合亲和力。2、它们表现出比BA更强的中和回避。2对三剂疫苗和BA的血浆有抑制作用。1例接种后感染，提示一种欧米克隆BA。基于1的疫苗可能不是诱导针对新出现的欧米克隆亚谱系的广谱保护的理想抗原。在另一项研究中
The recent global spread of the Omicron variant of severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) poses a critical challenge to the efficacy of COVID-19 vaccines and neutralizing therapeutic antibodies. This is due to multiple mutations in the spike protein (S), including its receptorbinding domain (RBD) and N-terminal domain. 1-3 In April 2022, BA. 1 was superseded by the BA. 2 subvariant. Currently, the BA. 2.12. 1 and BA. 4/5 subvariants have seen a dramatic increase and are dominant in the United States and South Africa, respectively. 4 These variants contain RBD sequences of the S protein identical to that of BA. 2, but with additional L452 and F486 mutations, namely L452Q (BA. 2.12. 1), L452M (BA. 2.13), L452R, F486V, and 69-70 deletion (BA. 4/5), and all showed a greater transmission advantage than BA. 2. The mutation at spike residue F486V (L452) reported in BA. 4/5 (both BA. 2.12. 1 and BA. 4/5) facilitates escape from some antibodies targeting the so-called class 1 and class 2 (class 2 and class 3) of the RBD but impairs spike affinity for the cellular receptor angiotensin converting enzyme 2 (ACE2). 5 However, reversion of L452R and R493Q restores binding affinity to hACE2 and thus fitness of BA. 4/5. 6Although BA. 2.12. 1 and BA. 4/5 have comparable ACE2 binding affinity to BA. 2, they show stronger neutralization avoidance than BA. 2 against plasma from three-dose vaccinations and from BA. 1 infections after vaccination, suggesting that an Omicron BA. 1-based vaccine may not be the ideal antigen to induce broad-spectrum protection against emerging Omicron sublineages. 7 In another study examining the efficacy of
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
64.8
作者：
Cao Y;Wang J;Jian F;Xiao T;Song W;Yisimayi A;Huang W;Li Q;Wang P;An R;Wang J;Wang Y;Niu X;Yang S;Liang H;Sun H;Li T;Yu Y;Cui Q;Liu S;Yang X;Du S;Zhang Z;Hao X;Shao F;Jin R;Wang X;Xiao J;Wang Y;Xie XS
通讯作者：
Xie XS
DOI：
10.1016/j.xcrm.2022.100529
发表时间：
2022-02-15
期刊：
Cell reports. Medicine
影响因子：
--
作者：
Edara VV;Manning KE;Ellis M;Lai L;Moore KM;Foster SL;Floyd K;Davis-Gardner ME;Mantus G;Nyhoff LE;Bechnak S;Alaaeddine G;Naji A;Samaha H;Lee M;Bristow L;Gagne M;Roberts-Torres J;Henry AR;Godbole S;Grakoui A;Saxton M;Piantadosi A;Waggoner JJ;Douek DC;Rouphael N;Wrammert J;Suthar MS
通讯作者：
Suthar MS
DOI：
10.1126/science.abn7591
发表时间：
2022-02-11
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
通讯作者：
--